| Name | Title | Contact Details |
|---|
ModivCare is a value-based healthcare services company that addresses the social determinants of health to drive positive health outcomes. As the healthcare industry`s leading non-emergency medical transportation provider for the last 35 years, ModivCare expanded on its long standing focus on transportation, a critical social determinant of health, in 2021 to form strategic partnerships to implement key technological advancements as well as care-centric solutions that account for all social determinants of health. From personal care to nutrition and meal delivery services, ModivCare enhances the customer experience and drives positive health outcomes to better people`s lives.
For over 30 years, Pentec Health has been an industry leader in providing patient-specific compounded sterile medications. Pentec Health’s medications are used for administration in dialysis centers, as well as providing in-home Specialty Infusion through nursing services and complex pharmaceutical products to patients who require access outside of a hospital setting. In addition, Pentec Health is now registered with the U.S. Food and Drug Administration (FDA) as a Human Drug Outsourcing Facility under section 503B of the Federal Food, Drug, and Cosmetic Act. Pentec Health has built a state of the art fully automated cGMP compliant facility that takes 503B manufacturing to the next level to ensure quality and safety by design.
Laughlin Memorial Hospital is a Greeneville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Navarro Regional Hospital is a Corsicana, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Signal Genetics is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in April 2010 after becoming the exclusive licensee to the world-renowned research on multiple myeloma (MM) performed at the University of Arkansas for Medical Sciences (UAMS). Signal Genetics’ flagship product - MyPRS (Myeloma Prognostic Risk Signature) is based upon more than two decades of clinical research on nearly 10,000 MM patients who received their care at UAMS. Signal Genetics offer the MyPRS test out of its state-of-the-art, CLIA certified reference laboratory located in Little Rock, AR. The company is dedicated to making its extensively validated diagnostic services available to all patients who need them. The mission of Signal Genetics is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions.